Please Note: Study Extended for Five Dogs
As of 2-10-2015, additional secured funding will allow us to enroll 5 more dogs onto this clinical trial. Please contact us if you think your dog might qualify for the study.
Purpose of study: The purpose of this pilot study is to evaluate whether vaccination with a new tumor-targeting cancer vaccine (ADXS31-164) combined with radiation therapy can decrease bone cancer pain and prolong overall survival in dogs with OSA.
Procedures covered by the study:
Dogs with suspected early OSA based on breed, clinical signs and radiographs
- Dogs that are otherwise systemically healthy (no cancer spread to the lungs, no other health problems such as kidney disease, liver disease, heart disease etc.)
- Dogs that are not candidates for amputation (either because they are too big or owners do not wish to pursue amputation)
- Dogs that have not received prior treatment for OSA (other than pain medications)
Physical examinations at each study visit (all visits take place at the University of Pennsylvania School of Veterinary Medicine).
- Bone biopsy.
- Two (2) doses of radiation therapy under general anesthesia.
- Blood tests and immune evaluation at enrollment and at each vaccination.
- Three complete staging evaluations including blood tests, urinalysis, limb radiographs, chest radiographs, ECG, and echocardiography.
- Eight doses of Listeria monocytogenes huHer-2/neu recombinant vaccine.
- Three days of antibiotics following each vaccine administration.
- The treatment of any toxicity directly resulting from vaccine administration.
Contact: Aliza Hildebrand Schmidt, MS, Clinical Research Coordinator